ABSTRACT
Purpose@#The purpose of this study is to identify health belief, subjective norms, social stigma, and sense of community affecting COVID-19 preventive behaviors among college students, and provide basic data for the development of preventive programs to improve COVID-19 preventive behaviors. @*Methods@#This study used a cross-sectional study design. The study recruited a total of 170 college students, through an online survey from three online communities which are mostly used by college students. Data were collected from July 24 to August 9, 2021. The SPSS 21.0 program was used to analyze the data using simple multiple regression. @*Results@#In simple multiple regression, the perceived susceptibility, perceived benefits and subjective norms were found to have a significant association with COVID-19 preventive behaviors of college students. These variables explained the 55.1% variance in COVID-19 preventive behaviors of college students (p<.001). @*Conclusion@#The results of this study showed that the perceived susceptibility, perceived benefits, and subjective norms were significant factors affecting COVID-19 preventive behaviors of college students. Based on the results of this study, it is expected to develop COVID-19 preventive programs and strategies that increase perceived susceptibility, perceived benefits, and subjective norms to improve the COVID-19 preventive behaviors of college students.
ABSTRACT
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in HBV-related HCC is not clear. METHODS: A retrospective cohort of 451 newly diagnosed, HBV-related HCC patients without antiviral therapy at diagnosis, who started antiviral therapy with either entecavir (n=249) or lamivudine (n=202), were enrolled. RESULTS: The median survival was longer for the entecavir group than for the lamivudine group, and lamivudine use (vs entecavir) was an independent factor for mortality (hazard ratio [HR], 1.49; p=0.002). Lamivudine use (vs entecavir) was an independent risk factor for new-onset hepatic decompensation (HR, 1.67; p=0.010) in 318 patients without previous hepatic decompensation, and it was also an independent risk factor for recurrence after curative therapy (HR, 1.84; p=0.002) in 117 patients who received curative therapy. The findings were similar in a propensity score-matched cohort. CONCLUSIONS: Overall survival, decompensation-free survival, and recurrence-free survival were better in the entecavir-treated patients than in the lamivudine treated-patients, indicating that the potent antiviral drug should be the preferred choice in HBV-related HCC patients.
Subject(s)
Humans , Antiviral Agents , Carcinoma, Hepatocellular , Cohort Studies , Diagnosis , Hepatitis B virus , Hepatitis B , Hepatitis B, Chronic , Hepatitis , Lamivudine , Mortality , Recurrence , Retrospective Studies , Risk FactorsABSTRACT
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in HBV-related HCC is not clear. METHODS: A retrospective cohort of 451 newly diagnosed, HBV-related HCC patients without antiviral therapy at diagnosis, who started antiviral therapy with either entecavir (n=249) or lamivudine (n=202), were enrolled. RESULTS: The median survival was longer for the entecavir group than for the lamivudine group, and lamivudine use (vs entecavir) was an independent factor for mortality (hazard ratio [HR], 1.49; p=0.002). Lamivudine use (vs entecavir) was an independent risk factor for new-onset hepatic decompensation (HR, 1.67; p=0.010) in 318 patients without previous hepatic decompensation, and it was also an independent risk factor for recurrence after curative therapy (HR, 1.84; p=0.002) in 117 patients who received curative therapy. The findings were similar in a propensity score-matched cohort. CONCLUSIONS: Overall survival, decompensation-free survival, and recurrence-free survival were better in the entecavir-treated patients than in the lamivudine treated-patients, indicating that the potent antiviral drug should be the preferred choice in HBV-related HCC patients.